GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
Phase 1
Withdrawn
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02380313
Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT02377401
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women
Phase 1
Completed
- Conditions
- Obstetric Labour, Premature
- Interventions
- Drug: Retosiban solution for InfusionDrug: Placebo
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT02377414
- Locations
- 🇺🇸
GSK Investigational Site, Glendale, California, United States
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women
Phase 4
Completed
- Conditions
- Diphtheria-Tetanus-acellular Pertussis Vaccines
- Interventions
- Biological: Boostrix™Drug: Saline placebo
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 688
- Registration Number
- NCT02377349
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor
Phase 3
Terminated
- Conditions
- Obstetric Labour, Premature
- Interventions
- Drug: Retosiban IV infusionDrug: Placebo IV infusion
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT02377466
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT02377427
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine
Completed
- Conditions
- Malaria
- Interventions
- Procedure: Blood collection
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36366
- Registration Number
- NCT02374450
- Locations
- 🇰🇪
GSK Investigational Site, Kisumu, Kenya
Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity
Not Applicable
Completed
- Conditions
- Dentine Sensitivity
- Interventions
- Device: Calcium sodium phosphosilicateOther: Sodium fluorideOther: Sodium monofluorophosphate
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 304
- Registration Number
- NCT02371616
- Locations
- 🇬🇧
GSK Investigational Site, Wirral, United Kingdom
Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Anaemia
- Interventions
- Drug: GSK1278863 25 mg TabletDrug: Pioglitazone 15 mg TabletDrug: Trimethoprim 100 mg TabletDrug: Rosuvastatin 10 mg Tablet
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT02371603
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Fluarix Tetra
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 121
- Registration Number
- NCT02369341
- Locations
- 🇧🇷
GSK Investigational Site, São Paulo, Brazil
© Copyright 2025. All Rights Reserved by MedPath